Form 4 for CRL Charles River Laboratories
Accepted 2026-02-02 00:00:00 ET · period of report 2026-01-30 · accession 0001100682-26-000012 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-02 | 2026-01-30 | CRL | FOSTER JAMES C | COB, Pres, CEO, Dir | F - Tax | $211.68 | -14.7K | 253.7K | -5% | -$3.10M | |
| 2026-02-02 | 2026-01-30 | CRL | FOSTER JAMES C | COB, Pres, CEO, Dir | A - Grant | $0.00 | +39.0K | 268.3K | +17% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-30 | F | D | 14,664 | $211.68 | 253,677 | D | — | — | |
| 2 | Common | Common Stock | 2026-01-30 | A | A | 39,031 | $0.00 | 268,341 | D | — | — | (F1) Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on May 26, 2023. (F2) Reflects the exempt transfer pursuant to Rule 16a-13 of (i) 14,577 shares from the 2024 GRAT account to direct holdings; and (ii) 4,048 shares from the 2022 GRAT account to direct holdings. |